Introduction {#Sec1}
============

Breast cancer is a common malignancy in the western world; it is estimated that more than 246,660 women in the USA will be diagnosed in 2016 with this disease \[[@CR1], [@CR2]\]. Most of these women are treated surgically with curative intent, although neoadjuvant chemotherapy may be given first to improve surgical options. Adjuvant therapy including hormonal and chemotherapy, as well as local radiation therapy, is a commonly used modality following definitive surgery to reduce the risk of local and systemic recurrence. Adjuvant chemotherapy has been shown to delay or prevent recurrence in early-stage breast cancer, and recent studies as well as ongoing work are helping to define the group of patients who are most likely to benefit from this treatment \[[@CR3], [@CR4]\]. A cancer diagnosis is psychologically distressing, and decisions about adjuvant therapy compound this distress. Alopecia is a disturbing side effect of almost all effective adjuvant chemotherapy regimens. Chemotherapy is associated with a number of toxicities, but alopecia is the most publicly visible sign of this treatment with psychological impact \[[@CR5]--[@CR8]\]. Scalp cooling to prevent chemotherapy-induced alopecia has been in use since the 1970s, and was recently cleared for marketing in the United States \[[@CR9]\]. Existing and emerging data have demonstrated excellent or good prevention of alopecia caused by commonly used chemotherapeutic regimens \[[@CR10]\]. The protection from alopecia offered by scalp cooling is thought to be due to both vasoconstriction resulting in reduced blood flow in the scalp, and reduced metabolic rate in the hair follicles \[[@CR6]\].

The primary concern that has limited the use of scalp cooling devices in the United States is the possibility that scalp cooling could increase the risk for scalp metastases \[[@CR10]\]. Scalp metastases are a rare site of metastatic disease in breast cancer \[[@CR11], [@CR12]\].

A recent review of the literature on scalp metastasis following adjuvant chemotherapy for early-stage breast cancer \[[@CR13]\] found it unlikely that the incidence of scalp metastasis might increase after scalp cooling. However, this study reviewed the incidence of both skin and scalp metastasis with and without adjuvant chemotherapy in patients with early- and late-stage breast cancer as well as other cancers, and with highly variable follow-up, which included patients on whom the follow-up time was not identified.

The intent of this systematic review and meta-analysis is to examine the effect of scalp cooling versus no scalp cooling on the incidence of scalp metastasis in patients being treating for breast cancer with adjuvant chemotherapy with identified follow-up.

Methods {#Sec2}
=======

A systematic review of the literature was undertaken using the following search terms: chemotherapy AND breast cancer AND scalp metastas\*.

The following electronic databases were searched:PubMed (searched on October 13, 2016 & February 15, 2017)Google (searched on October 13, 2106 & February 15, 2017; first 4 pages of hits)

The following online journals were searched:Breast Cancer Research and Treatment (searched on October 13, 2016 & February 15, 2017)Supportive Care in Cancer (searched on October 13, 2016 & February 15, 2017)European Journal Oncology Nursing (searched on October 13, 2016 & February 15, 2017)European Journal Cancer (searched on October 13, 2016 & February 15, 2017)Journal Clinical Oncology (searched on October 13, 2016 & February15, 2017).

Hand searches of all articles included in the analysis were undertaken on October 14--15, 2016 & February 16--17, 2017.

Two authors independently reviewed each of the studies and used a data collection form to determine inclusion eligibility (see Appendix 1). A third author acted as arbiter in those situations where disagreement existed between the first two authors.

Inclusion criteria used in the qualitative and quantitative (meta-analysis) review {#Sec3}
----------------------------------------------------------------------------------

Articles which evaluated patients treated for breast cancer with chemotherapy and, with and without the use of scalp cooling technology and, examined the longer-term sequelae of this therapy (with identified follow-up timeframes) including scalp metastasis were included in this analysis.

Exclusion criteria used {#Sec4}
-----------------------

Patients who had other types of early-stage cancers, studies that did not examine longer-term sequelae (i.e., only reported on the immediate short term results of the cancer treatment), and studies including patients who were not treated with chemotherapy were excluded from the analysis.

Statistical analysis {#Sec5}
--------------------

MedCalc statistical software (Version 16.8.4) was used to calculate the incidence rates and confidence intervals of the combined studies with and without the use of scalp cooling over time. A *P* value was then calculated to determine if there were a statistically meaningful difference between the two rates. A weighted (weighted based on the number of patients in each trial) average of the follow-up durations was then calculated along with standard deviations.

Results {#Sec6}
=======

Figure [1](#Fig1){ref-type="fig"} shows the identification, screening, eligibility, and inclusion as part of the systematic review. A total of 24 full-text studies were identified as eligible for review.Fig. 1PRISMA 2009 flow diagram

Included studies {#Sec7}
----------------

Ten studies which reported on scalp metastasis were included in the analysis, of which five reported on scalp cooling only \[[@CR13]--[@CR17]\], four reported on scalp cooling versus no scalp cooling \[[@CR11], [@CR18]--[@CR20]\], and one on no scalp cooling \[[@CR12]\] (Table [1](#Tab1){ref-type="table"}).Table 1Included StudiesStudyScalp coolingNo scalp coolingLength of follow-up (months) scalp cooling medianWeighted length of follow-up scalp coolingLength of follow-up (months) no scalp cooling medianWeighted length of follow-up no scalp coolingCharacteristicsScalp metsTotal ptsScalp metsTotal patsLemieux et al. \[[@CR11]\]65531876919.478644.498First time breast cancer patients. Study undertaken in Canada. Mainly T1 and T2 tumor size; stage 1 & 2, treated with mainly cyclophosphamides and doxorubicinParker \[[@CR14]\]06120.037Stage 4 recurrent disease. Treated with IV CMF (2 cycles)Protiere et al. \[[@CR18]\]0770109441.729First time breast cancer patients. 4 cycles of adjuvant IV chemotherapy with mitoxantrone + cyclophosphamide. Antiemetics also administered. Study undertaken in FranceRidderheim \[[@CR15]\]03150.023Adjuvant treatment breast cancerRon et al. \[[@CR19]\]019016140.136140.181Breast cancer patients treated with cyclophosphamide, methotrexate, and 5- fluorouracil \[CMF\]; unclear as to stage of breast cancerRugo \[[@CR17]\]010129.51.521Early-stage breast cancer patientsSpaëth et al. \[[@CR20]\]377001413614.150364.10093% breast cancer patients. Treated with IV chemo mainly anthracyclines and/or taxotere. Unclear as to stage of breast cancerTollenaar et al. \[35\]035460.822Patients treated with cyclophosphamide + doxorubicin + 5-fluorouracil on first operative day (one course of treatment). Unclear as to stage of cancervan de Sande \[[@CR12]\]488511078.635Stage 4 + lymph nodesvan den Hurk et al. \[[@CR13]\]3395265.242treated with CMF; unclear as to stage of breast cancerTotals12195951238Averages32.3943.145687.41

Excluded studies {#Sec8}
----------------

Fourteen studies were excluded for the following reasons: No follow-up or unclear follow-up time following completion of chemotherapy (total of 10) \[[@CR21]--[@CR30]\]; patients used scalp cooling for treatment of metastatic disease (total of 2) \[[@CR31], [@CR32]\]; treatment for breast cancer was not specified (one study) \[[@CR33]\]; and one study was excluded due to unclear cancer type at presentation \[[@CR34]\] (Table [2](#Tab2){ref-type="table"}).Table 2Studies excluded with reasonsStudyReason for exclusionChristodoulou \[[@CR21]\]Zero out of 30 breast cancer patients developed a scalp metastasis. However, there was no mention of the follow-up time in this patient cohort. Scalp cooling was employedCampos-Gomez \[[@CR23]\]Sixty-eight patients in scalp cooling were reported as followed up on, but it was unclear as to the timeframe of follow-up. No mention as well of scalp metastasisChristodoulou \[[@CR22]\]Two out of 227 breast cancer patients developed scalp metastasis. However, there was no mention of the follow-up time in this patient cohort. Scalp cooling was employedDean \[[@CR24]\]Fifty-eight breast cancer patients treated with doxorubicin and with scalp cooling were reported on for scalp metastasis, but there was no mention of the follow-up timeJohansen \[[@CR31]\]One patient in scalp cooling group who already had metastatic breast cancer (in the liver) experienced scalp metastasis (*n* = 61); all patients in group already had metastatic primary or recurrent cancer originating from the breastKargar \[[@CR34]\]Unclear as to type of primary cancer patients hadLemenager \[[@CR32]\]Breast cancer patients treated with chemotherapy (*n* = 88); all had metastatic disease and were treated with scalp hypothermia. No mention of scalp metastasisLookingbill \[[@CR33]\]No mention of how patients with breast cancer were treated; There were 18 patients with scalp metastases out of 707 primary breast cancer patients. (18/707 = 2.5%). There was also no mention of the follow-up time as to when scalp metastases occurredMassey \[[@CR25]\]Breast cancer patients treated with chemotherapy (*n* = 94) treated with Paxman cooling system. None of these patients developed scalp metastases during the study period. Unclear as to the length of follow-up on these patientsMiddleton et al. \[[@CR26]\]Twenty-four patients with breast cancer receiving adjuvant chemotherapy. No length of follow-up noted. No scalp metastases notedNangia et al. \[[@CR30]\]No long-term follow-up on patients in randomized controlled trialPeck et al. \[[@CR27]\]One patient in scalp cooling group subsequently presented with scalp metastasis. However, patient already had widespread metastatic cancer (*n* = 10); unclear as to follow-upSatterwhite \[[@CR28]\]One patient in scalp cooling group already had scalp metastasis (*n* = 12); no follow-upvan den Hurk \[[@CR29]\]Breast cancer patients treated with chemotherapy in the Dutch scalp cooling registry (*n* = 1216). No patients developed scalp metastasis during the study period of 2006--2009. However, unclear as to the length of follow-up on these patients

Effect of scalp cooling vs non-scalp cooling on the outcome of scalp metastasis {#Sec9}
-------------------------------------------------------------------------------

There were 12 cases of scalp metastases out of 1959 patients where scalp cooling was employed (Table [1](#Tab1){ref-type="table"}). The incidence rate was 0.61% (95% CI 0.32--1.1%). These patients were followed for an estimated mean of 43.14 months (weighted mean average). There were 5 cases of scalp metastasis out of 1238 patients where scalp cooling was not used (Table [1](#Tab1){ref-type="table"}). The incidence rate was 0.4% (95% CI 0.13--0.9%). These patients were followed for an estimated mean of 87.4 months (weighted mean average). There was no statistically meaningful difference between the two comparison groups (with and without scalp cooling) (*P* = 0.43).

Discussion {#Sec10}
==========

The possibility that scalp cooling protects the scalp from the beneficial effects of adjuvant chemotherapy has been a concern that has limited the use of these devices in the United States. However, this systematic review and meta-analysis examining patients with breast cancer receiving chemotherapy while using scalp cooling for hair preservation does not support this concern and, demonstrates no statistical difference in the incidence of scalp metastasis between patients using scalp cooling vs. no scalp cooling. This analysis further complements the van den Hurk 2013 study \[[@CR13]\] (which also found no statistically meaningful difference) and adds additional longer-term study data (with confirmed duration of follow-up of breast cancer specifically to identify scalp metastasis) to further substantiate the low incidence of scalp metastases \[[@CR15], [@CR18], [@CR35]\].

Scalp metastases occur rarely in breast cancer (with metastases more commonly occurring in other areas of skin including chest wall \[[@CR36]\]) and, as reviewed above, scalp metastases seem to accompany and usually occur following the diagnosis of widespread metastatic disease. Interestingly, in a sensitivity analysis which added back those studies that were excluded due to no mention of follow-up time and/or type of cancer treatment but where breast cancer was identified as the primary source, scalp cooling and no scalp cooling were identified, no other metastatic cancer was present, and scalp metastases were identified \[[@CR22], [@CR24]--[@CR26], [@CR29], [@CR33]\]; a statistically significant difference in the incidence of scalp cooling between scalp cooling and no scalp cooling was found \[[@CR11]--[@CR20]\] (scalp cooling incidence 0.4%; 95% CI 0.21--0.66% vs. no scalp cooling: 1.2%; 95% CI 0.75--1.8%; *P* = 0.006).

Additional questions considered {#Sec11}
-------------------------------

Does adjuvant chemotherapy reduce the risk for scalp metastases in breast cancer patients? The ability of adjuvant chemotherapy to specifically reduce scalp metastases presumes that there are dormant micrometastatic cells already seeded in the scalp from the primary tumor at the time of diagnosis of early-stage disease. However, it is much more likely that adjuvant chemotherapy effects occult metastatic cells in other sites that might eventually metastasize to the scalp \[[@CR37]\], as this site (scalp) of metastatic disease is uncommon.

Does scalp cooling increase the incidence of scalp metastases as the first sign of recurrent breast cancer? Scalp metastases are very rarely reported as the first site of metastatic recurrence in patients with early-stage breast cancer. The National Surgical Adjuvant Breast and Bowel Project (NSABP) reported in a communication to Judith Dean \[[@CR38]\] that two patients in a sample of 7800 women had metastases to scalp as the first site of recurrent disease. One of these patients had received adjuvant chemotherapy. The incidence of scalp metastases as the first site of recurrence can therefore be estimated to be around 0.025% (2/7800).

Is it possible that scalp cooling used in conjunction with adjuvant chemotherapy increases the risk for scalp metastases as the site for first recurrence? Based on available data, this appears to be highly unlikely. Two cases of scalp metastases as the first detected metastatic site in patients with breast cancer previously treated with adjuvant chemotherapy together with scalp cooling were described by Lemieux \[[@CR39]\]. The first patient presented with a scalp metastasis as the first site of metastatic disease 9 years following breast cancer chemotherapy, but had only used scalp cooling during 2 of 4 cycles of doxorubicin and cyclophosphamide. Many other sites of metastases were found in this patient a few months later. The second patient used scalp cooling in only one out of 6 cycles of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil, and then was treated for a local recurrence 5 years later with surgery and 6 cycles of epirubicin 100 mg/m^2^ without scalp cooling. It is highly unlikely that scalp cooling used in one out of 12 chemotherapy cycles in this patient at high risk for recurrent disease contributed to the finding of a scalp metastasis 7 years after her initial diagnosis. In both cases, it is quite unlikely that there is any association of scalp cooling with subsequent development of a scalp metastasis.

Considering the exceedingly low incidence of scalp metastasis as a first site of recurrence (or in general), the risk appears small for scalp cooling to increase the incidence of scalp metastases in patients with breast cancer. In addition, the concept that scalp cooling could increase the incidence of metastases to the scalp suggests dormant cells in the scalp are responsible for recurrence---again unlikely. Based on what is now understood about the biology of breast cancer, and the low incidence of scalp metastases as the site of first recurrence, it is very unlikely that scalp cooling contributes to the risk of metastatic recurrence.

Study limitations {#Sec12}
-----------------

The analysis undertaken was retrospective in nature. As well, most studies did not examine scalp metastasis as a primary endpoint. These types of studies have inherent biases.

The scalp cooling comparison arm (*n* = 1,959) evaluated patients over an estimated weighted mean of 42.1 months versus an estimated weighted mean of 87.4 months for non-scalped-cooled patients. The assumption in calculating these weighted mean averages was that the distributions from which the sample means came from were relatively normal (bell-shaped and symmetric). Further, since the sample sizes of several of the studies evaluated were large \[[@CR7], [@CR11]--[@CR13], [@CR17], [@CR18]\] (comprising over 98% of the patients evaluated), the median and mean were assumed to be fairly close in value. Based on these factors, we believe the weighted mean value is a reasonable approximation of the follow-up timeframes. Follow-up on scalp cooling patients over a longer period of time is ongoing \[[@CR17], [@CR30]\].

Conclusion {#Sec13}
==========

Based on this extensive review and meta-analysis, scalp cooling is highly unlikely to increase the incidence of scalp metastases in patients with early-stage breast cancer receiving adjuvant chemotherapy. Van den Hurk 2013 \[[@CR13]\] stated: "We found it rather unlikely that the incidence of scalp metastases might increase at all after scalp cooling and; that a very small proportion of patients receiving chemotherapy (with or without scalp cooling) are at risk for developing metastases at this site." Based on this analysis, we would concur with van den Hurk.
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